Alpha-fetoprotein
Hepatocellular carcinoma
Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein
Protein induced by vitamin K absence or antagonist-II
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
28 Jul 2021
28 Jul 2021
Historique:
received:
27
01
2021
revised:
10
03
2021
accepted:
13
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
11
8
2021
Statut:
ppublish
Résumé
Diagnostic accuracy of various tumor markers and their combinations for hepatocellular carcinoma (HCC) was not fully investigated. To evaluate the diagnostic accuracy of alpha-fetoprotein (AFP), the Patients with newly detected liver mass or elevated serum AFP levels were considered eligible. Serum AFP level, AFP-L3 fraction, and PIVKA-II level were measured at the first visit. In total, 622 patients were included; 355 patients (57.1%) had chronic liver disease, and 208 (33.4%) had liver cirrhosis. HCC was diagnosed in 160 patients (25.7%). The area under the receiver operating characteristics curves (AUROCs) of the serum AFP, AFP-L3 fraction, AFP-L3, and PIVKA-II levels for the diagnosis of HCC were 0.775, 0.792, 0.814, and 0.834, respectively. A novel diagnostic model was developed by classifying patients in a 1:1 ratio into training and validation sets. Using the binary regression analysis of the training cohort, the AFP, AFP-L3 fraction, and PIVKA-II (ALPs) score was calculated as follows: ALPs score = 3.8 × [serum AFP level (ng/mL) × AFP-L3 fraction (%) × 0.01] + 0.2 × PIVKA-II level (mAU/mL). The AUROC of the ALPs score for diagnosis of HCC was 0.878, significantly higher than that of serum AFP level ( The ALPs score calculated using serum AFP level, AFP-L3 fraction, and PIVKA-II level showed improved accuracy in HCC diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Diagnostic accuracy of various tumor markers and their combinations for hepatocellular carcinoma (HCC) was not fully investigated.
AIM
OBJECTIVE
To evaluate the diagnostic accuracy of alpha-fetoprotein (AFP), the
METHODS
METHODS
Patients with newly detected liver mass or elevated serum AFP levels were considered eligible. Serum AFP level, AFP-L3 fraction, and PIVKA-II level were measured at the first visit.
RESULTS
RESULTS
In total, 622 patients were included; 355 patients (57.1%) had chronic liver disease, and 208 (33.4%) had liver cirrhosis. HCC was diagnosed in 160 patients (25.7%). The area under the receiver operating characteristics curves (AUROCs) of the serum AFP, AFP-L3 fraction, AFP-L3, and PIVKA-II levels for the diagnosis of HCC were 0.775, 0.792, 0.814, and 0.834, respectively. A novel diagnostic model was developed by classifying patients in a 1:1 ratio into training and validation sets. Using the binary regression analysis of the training cohort, the AFP, AFP-L3 fraction, and PIVKA-II (ALPs) score was calculated as follows: ALPs score = 3.8 × [serum AFP level (ng/mL) × AFP-L3 fraction (%) × 0.01] + 0.2 × PIVKA-II level (mAU/mL). The AUROC of the ALPs score for diagnosis of HCC was 0.878, significantly higher than that of serum AFP level (
CONCLUSION
CONCLUSIONS
The ALPs score calculated using serum AFP level, AFP-L3 fraction, and PIVKA-II level showed improved accuracy in HCC diagnosis.
Identifiants
pubmed: 34366629
doi: 10.3748/wjg.v27.i28.4687
pmc: PMC8326250
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Plant Lectins
0
Protein Precursors
0
alpha-Fetoproteins
0
lentil lectin
0
Prothrombin
9001-26-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4687-4696Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Authors have nothing to disclose.
Références
Scand J Gastroenterol. 2016 Mar;51(3):344-53
pubmed: 26340708
Gastroenterology. 2010 Feb;138(2):493-502
pubmed: 19852963
Gastroenterology. 2003 Jul;125(1):89-97
pubmed: 12851874
Liver Cancer. 2013 Aug;2(3-4):151-2
pubmed: 24400219
Gastroenterology. 2009 Jul;137(1):110-8
pubmed: 19362088
Medicine (Baltimore). 2017 Mar;96(11):e5811
pubmed: 28296720
J Clin Gastroenterol. 2002 Nov-Dec;35(5):398-402
pubmed: 12394228
Lancet. 2014 May 17;383(9930):1749-61
pubmed: 24480518
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Hepatol. 2015 Apr;62(4):848-54
pubmed: 25450201
Liver Cancer. 2013 Jan;2(1):31-9
pubmed: 24159594
Am J Gastroenterol. 2006 Sep;101(9):2038-43
pubmed: 16848811
Clin Mol Hepatol. 2019 Sep;25(3):223-233
pubmed: 30661336
Clin Gastroenterol Hepatol. 2009 Jan;7(1):104-13
pubmed: 18849011
Radiology. 1983 Sep;148(3):839-43
pubmed: 6878708
N Engl J Med. 1984 May 31;310(22):1427-31
pubmed: 6201741
World J Gastroenterol. 2013 Jan 21;19(3):339-46
pubmed: 23372355
World J Gastroenterol. 2015 Oct 7;21(37):10573-83
pubmed: 26457017
Dis Markers. 2018 Oct 4;2018:8906023
pubmed: 30402170
Hepatology. 2011 Mar;53(3):885-94
pubmed: 21319193
Clin Mol Hepatol. 2019 Sep;25(3):245-263
pubmed: 30759967
Hepatol Res. 2012 Sep;42(9):887-94
pubmed: 22524419
Z Gastroenterol. 2016 Dec;54(12):1296-1305
pubmed: 27936479
Ther Adv Med Oncol. 2019 Sep 06;11:1758835919869120
pubmed: 31523283
J Magn Reson Imaging. 2017 Sep;46(3):783-792
pubmed: 28083902
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Radiology. 2016 Oct;281(1):129-39
pubmed: 27115054
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Gastroenterol Hepatol. 2007 Mar;5(3):394-402; quiz 267
pubmed: 17368240